Ocrelizumab (Ocrevus)
Ocrelizumab (Ocrevus) is a medication administered by IV infusion for the treatment of relapsing and primary progressive forms of MS. Ocrelizumab is a humanized monoclonal antibody that targets CD20 positive B lymphocytes which contribute to nerve damage in MS.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.